A5052948894- Cancer Immunotherapy and Biomarkers
- Pneumocystis jirovecii pneumonia detection and treatment
- Simulation-Based Education in Healthcare
- Health and Well-being Studies
- Family and Patient Care in Intensive Care Units
- Macrophage Migration Inhibitory Factor
- Autoimmune Bullous Skin Diseases
- Sexual Differentiation and Disorders
- Lung Cancer Treatments and Mutations
- Immunodeficiency and Autoimmune Disorders
- Vasculitis and related conditions
- Hormonal and reproductive studies
- Vascular Malformations and Hemangiomas
- Chemical Safety and Risk Management
- Cancer, Stress, Anesthesia, and Immune Response
- Inflammatory mediators and NSAID effects
- Cell Adhesion Molecules Research
- Ocular Diseases and Behçet’s Syndrome
- Advanced Breast Cancer Therapies
- Blood groups and transfusion
- Gout, Hyperuricemia, Uric Acid
- Alkaline Phosphatase Research Studies
- Biomedical and Engineering Education
- Colorectal Cancer Treatments and Studies
- Prostate Cancer Treatment and Research
Brown University
2021-2024
Rhode Island Hospital
2021-2023
Roger Williams Medical Center
2021-2022
Providence College
2021
Lahey Medical Center
2019-2020
St. Vincent's University Hospital
2017
Indiana University School of Medicine
2017
University College Dublin
2014-2017
Rolls-Royce (United Kingdom)
1964
The cytokine macrophage migration inhibitory factor (MIF) possesses unique tautomerase enzymatic activity, which contributes to the biological functional activity of MIF. In this study, we investigated effects blocking hydrophobic active site MIF in pathogenesis lung cancer. To address this, initially established a Lewis carcinoma (LLC) murine model Mif-KO and wild-type (WT) mice compared tumor growth knock-in mouse expressing mutant lacking (MifP1G). Primary was significantly attenuated...
Macrophage migration inhibitory factor (MIF) is a key proinflammatory mediator that we have previously shown to be associated with an aggressive clinical phenotype in cystic fibrosis. It possesses unique tauto-merase enzymatic activity. However, date, no human-derived substrate has been identified the capacity interact this cytokine's tautomerase This led us hypothesize MIF may external substrates. We describe for first time how Pseudomonas aeruginosa can utilize human recombinant (rMIF)...
TPS115 Background: Celecoxib is a selective COX-2 inhibitor licensed for the treatment of chronic arthritis. However, an association between non-steroidal anti-inflammatory drug (NSAID) use and decreased breast cancer risk in women has also been demonstrated (Harris et al, Epidemiology, 1996), believed to be due inhibition enzyme. Preclinical data shown that inhibitors can prevent mammary tumour formation Can Res, 2000), inhibit angiogenesis (Rozic Int J Cancer, 2001) reverse resistance...
The use of immune checkpoint inhibitors (ICI) has transformed cancer treatment. Subsequent ICI become increasingly common following disease progression. We aim to evaluate the safety and tolerability sequential treatment modality.Retrospective review confirmed carcinoma from January 2014 December 2018. Patients were categorized into "initial arm" "sequential defined as patients receiving single, dual or chemo-immunotherapy an initial regimen. Primary outcome was development a new recurrent...
Summary It is now generally recognised that liquid hydrogen offers a considerable increase in vehicle performance over the more conventional fuels, despite its relatively low density. A design study on an upper stage, which uses hydrogen/ oxygen chemical propulsion system, revealed number of problem areas extend beyond current levels experience and knowledge rocket technology existing U.K. This was made third stage communication satellite launching vehicle, problems high-lighted during...
<h3>Background</h3> ICI revolutionized modern Oncology landscape and being utilized in metastatic to adjuvant neo-adjuvant settings. As Oncologists, we are treating cancer patients with every day, yet there is still a lot that unknown about these drugs. We don't have clear understanding of the efficacy toxicity when sequencing one for another. conducted retrospective review real world data at Lahey Hospital Medical Center understand further pave path prospective studies this issue improve...
Disclosure form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.
e18835 Background: Immune checkpoint inhibitors (ICI) up regulate T cell activity promoting tumor death and revolutionized modern oncology. The use number of indications for ICI is growing at an unprecedented speed. Combination sequential therapies have been shown to be beneficial in certain types cancer. There no significant data support non-FDA approved when patients develop toxicities or progression which could result a financial burden on the patient health care system. We conducted...